Lymphoseek tilmanocept regulatory update

Navidea disclosed in its 3Q13 earnings that the Centers for Medicare & Medicaid Services (CMS) issued a C-code for pass-through reimbursement of Lymphoseek tilmanocept, which is marketed in the U.S. f...